B. Maru

565 total citations
16 papers, 393 citations indexed

About

B. Maru is a scholar working on Genetics, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, B. Maru has authored 16 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 7 papers in Molecular Biology and 4 papers in Psychiatry and Mental health. Recurrent topics in B. Maru's work include Neurogenetic and Muscular Disorders Research (9 papers), CRISPR and Genetic Engineering (3 papers) and Congenital Anomalies and Fetal Surgery (3 papers). B. Maru is often cited by papers focused on Neurogenetic and Muscular Disorders Research (9 papers), CRISPR and Genetic Engineering (3 papers) and Congenital Anomalies and Fetal Surgery (3 papers). B. Maru collaborates with scholars based in United States, United Kingdom and France. B. Maru's co-authors include Omar Dabbous, Douglas M. Sproule, Douglas E. Feltner, I. Jensen, A. Simon Pickard, Kavitha Kotha, Daniel C. Malone, John T. Kissel, Jerry R. Mendell and Richard Shell and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

B. Maru

16 papers receiving 383 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Maru United States 6 243 204 145 79 39 16 393
Kavitha Kotha United States 8 139 0.6× 148 0.7× 91 0.6× 48 0.6× 7 0.2× 13 320
Arlene D’Silva Australia 14 323 1.3× 239 1.2× 208 1.4× 55 0.7× 12 0.3× 23 487
Crystal M. Proud United States 9 124 0.5× 170 0.8× 68 0.5× 58 0.7× 13 0.3× 25 281
David Schorling Germany 10 408 1.7× 325 1.6× 241 1.7× 76 1.0× 10 0.3× 18 526
Tamara Dangouloff Belgium 9 399 1.6× 276 1.4× 257 1.8× 50 0.6× 8 0.2× 21 468
Rachel Salazar United States 8 202 0.8× 161 0.8× 146 1.0× 11 0.1× 24 0.6× 24 363
Jena M. Krueger United States 6 153 0.6× 127 0.6× 99 0.7× 46 0.6× 12 0.3× 13 228
Kerry L. Flynn United States 5 450 1.9× 338 1.7× 271 1.9× 40 0.5× 168 4.3× 5 715
Alexandra Prufer de Queiroz Campos Araújo Brazil 7 119 0.5× 120 0.6× 69 0.5× 13 0.2× 21 0.5× 17 223
Marc‐Olivier Deguise Canada 13 307 1.3× 246 1.2× 118 0.8× 13 0.2× 17 0.4× 25 405

Countries citing papers authored by B. Maru

Since Specialization
Citations

This map shows the geographic impact of B. Maru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Maru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Maru more than expected).

Fields of papers citing papers by B. Maru

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Maru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Maru. The network helps show where B. Maru may publish in the future.

Co-authorship network of co-authors of B. Maru

This figure shows the co-authorship network connecting the top 25 collaborators of B. Maru. A scholar is included among the top collaborators of B. Maru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Maru. B. Maru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Maru, B., et al.. (2023). CO204 Primary and Secondary Endpoints Used in Recent (2022) Alzheimer’s Disease (AD) Phase III Clinical Trials. Value in Health. 26(6). S53–S54. 1 indexed citations
2.
Sullivan, Joseph, Alison Deighton, Maria Candida Vila, et al.. (2022). The clinical, economic, and humanistic burden of Dravet syndrome – A systematic literature review. Epilepsy & Behavior. 130. 108661–108661. 43 indexed citations
3.
Dabbous, Omar, et al.. (2022). 253  Economic burden of care and treatment options for Rett syndrome: two systematic literature reviews. Journal of Neurology Neurosurgery & Psychiatry. 93(6). A86.3–A86. 1 indexed citations
4.
Jensen, I., B. Maru, Douglas M. Sproule, et al.. (2021). An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). SHILAP Revista de lepidopterología. 9(1). 1889841–1889841. 32 indexed citations
5.
Taieb, V., et al.. (2019). PRO35 ECONOMIC BURDEN OF CARE IMPOSED ON PATIENTS WITH RETT SYNDROME: A SYSTEMATIC LITERATURE REVIEW. Value in Health. 22. S341–S341. 1 indexed citations
6.
7.
8.
Dabbous, Omar, Douglas M. Sproule, Douglas E. Feltner, et al.. (2019). Event-Free Survival and Motor Milestone Achievement Following AVXS-101 and Nusinersen Interventions Contrasted to Natural History for Type I Spinal Muscular Atrophy Patients (S25.005). Neurology. 92(15_supplement). 4 indexed citations
9.
10.
11.
Dabbous, Omar, B. Maru, Jeroen P. Jansen, et al.. (2019). Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Advances in Therapy. 36(5). 1164–1176. 62 indexed citations
12.
Malone, Daniel C., I. Jensen, B. Maru, et al.. (2019). Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. SHILAP Revista de lepidopterología. 7(1). 1601484–1601484. 76 indexed citations
13.
Lloyd, Andrew, Robert S. Dean, I. Jensen, B. Maru, & Omar Dabbous. (2018). PRM209 - HOW DO WE MEASURE UTILITIES OUTSIDE OF TRIALS IN RARE DISEASES?. Value in Health. 21. S392–S392. 1 indexed citations
14.
Pickard, A. Simon, Kavitha Kotha, Lindsay N. Alfano, et al.. (2018). Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy. Pediatric Pulmonology. 54(2). 179–185. 158 indexed citations
15.
Fuller, Louise, et al.. (2015). Successful treatment of a patient with severe atopic dermatitis and severe asthma by centrifugal therapeutic plasma exchange. BMJ Case Reports. 2015. bcr2014209008–bcr2014209008. 1 indexed citations
16.
Maru, B., Jonathan H. Tobias, Caroline Rivers, et al.. (2008). Potential use of an estrogen–glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 44(1). 102–112. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kavitha Kotha Breakdown of academic impact, for papers by Arlene D’Silva Breakdown of academic impact, for papers by Crystal M. Proud Breakdown of academic impact, for papers by David Schorling Breakdown of academic impact, for papers by Tamara Dangouloff Breakdown of academic impact, for papers by Rachel Salazar Breakdown of academic impact, for papers by Jena M. Krueger Breakdown of academic impact, for papers by Kerry L. Flynn Breakdown of academic impact, for papers by Alexandra Prufer de Queiroz Campos Araújo Breakdown of academic impact, for papers by Marc‐Olivier Deguise
Rankless by CCL
2026